Logo image of IMNM

IMMUNOME INC (IMNM) Stock Fundamental Analysis

NASDAQ:IMNM - US45257U1088 - Common Stock

10.3 USD
+0.35 (+3.52%)
Last: 8/22/2025, 8:16:19 PM
10.3 USD
0 (0%)
After Hours: 8/22/2025, 8:16:19 PM
Fundamental Rating

3

Taking everything into account, IMNM scores 3 out of 10 in our fundamental rating. IMNM was compared to 547 industry peers in the Biotechnology industry. IMNM has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, IMNM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMNM has reported negative net income.
IMNM had a negative operating cash flow in the past year.
IMNM had negative earnings in each of the past 5 years.
In the past 5 years IMNM always reported negative operating cash flow.
IMNM Yearly Net Income VS EBIT VS OCF VS FCFIMNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

IMNM has a worse Return On Assets (-71.68%) than 61.57% of its industry peers.
IMNM has a Return On Equity (-78.87%) which is in line with its industry peers.
Industry RankSector Rank
ROA -71.68%
ROE -78.87%
ROIC N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
IMNM Yearly ROA, ROE, ROICIMNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNM Yearly Profit, Operating, Gross MarginsIMNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

IMNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMNM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMNM has been increased compared to 5 years ago.
There is no outstanding debt for IMNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMNM Yearly Shares OutstandingIMNM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IMNM Yearly Total Debt VS Total AssetsIMNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 16.02 indicates that IMNM is not in any danger for bankruptcy at the moment.
IMNM's Altman-Z score of 16.02 is amongst the best of the industry. IMNM outperforms 90.35% of its industry peers.
There is no outstanding debt for IMNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.02
ROIC/WACCN/A
WACC9.73%
IMNM Yearly LT Debt VS Equity VS FCFIMNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

IMNM has a Current Ratio of 12.13. This indicates that IMNM is financially healthy and has no problem in meeting its short term obligations.
IMNM's Current ratio of 12.13 is amongst the best of the industry. IMNM outperforms 84.88% of its industry peers.
IMNM has a Quick Ratio of 12.13. This indicates that IMNM is financially healthy and has no problem in meeting its short term obligations.
IMNM has a better Quick ratio (12.13) than 84.88% of its industry peers.
Industry RankSector Rank
Current Ratio 12.13
Quick Ratio 12.13
IMNM Yearly Current Assets VS Current LiabilitesIMNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.34% over the past year.
Looking at the last year, IMNM shows a quite strong growth in Revenue. The Revenue has grown by 16.68% in the last year.
EPS 1Y (TTM)45.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.04%
Revenue 1Y (TTM)16.68%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%69.84%

3.2 Future

IMNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.21% yearly.
The Revenue is expected to grow by 91.74% on average over the next years. This is a very strong growth
EPS Next Y55.32%
EPS Next 2Y23%
EPS Next 3Y15.98%
EPS Next 5Y15.21%
Revenue Next Year-26.42%
Revenue Next 2Y36.91%
Revenue Next 3Y106.11%
Revenue Next 5Y91.74%

3.3 Evolution

IMNM Yearly Revenue VS EstimatesIMNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMNM Yearly EPS VS EstimatesIMNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMNM. In the last year negative earnings were reported.
Also next year IMNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNM Price Earnings VS Forward Price EarningsIMNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNM Per share dataIMNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

IMNM's earnings are expected to grow with 15.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23%
EPS Next 3Y15.98%

More info and screens

0

5. Dividend

5.1 Amount

IMNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOME INC

NASDAQ:IMNM (8/22/2025, 8:16:19 PM)

After market: 10.3 0 (0%)

10.3

+0.35 (+3.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners84.44%
Inst Owner Change-0.71%
Ins Owners1.68%
Ins Owner Change4.67%
Market Cap896.62M
Analysts86.67
Price Target25.06 (143.3%)
Short Float %18.46%
Short Ratio15.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.23%
Min EPS beat(2)7.32%
Max EPS beat(2)25.15%
EPS beat(4)2
Avg EPS beat(4)-30.32%
Min EPS beat(4)-116.8%
Max EPS beat(4)25.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)677.56%
Min Revenue beat(2)451.08%
Max Revenue beat(2)904.04%
Revenue beat(4)3
Avg Revenue beat(4)343.48%
Min Revenue beat(4)-14.94%
Max Revenue beat(4)904.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.29%
PT rev (3m)3.82%
EPS NQ rev (1m)-2.19%
EPS NQ rev (3m)27.99%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)1.22%
Revenue NQ rev (1m)-80.06%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)44.01%
Revenue NY rev (3m)157.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 71.22
P/FCF N/A
P/OCF N/A
P/B 3.33
P/tB 3.33
EV/EBITDA N/A
EPS(TTM)-3.08
EYN/A
EPS(NY)-2.46
Fwd EYN/A
FCF(TTM)-2.26
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0.14
BVpS3.09
TBVpS3.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.68%
ROE -78.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 636.63%
Cap/Sales 143.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.13
Quick Ratio 12.13
Altman-Z 16.02
F-Score6
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)906.42%
Cap/Depr(5y)561.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.04%
EPS Next Y55.32%
EPS Next 2Y23%
EPS Next 3Y15.98%
EPS Next 5Y15.21%
Revenue 1Y (TTM)16.68%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%69.84%
Revenue Next Year-26.42%
Revenue Next 2Y36.91%
Revenue Next 3Y106.11%
Revenue Next 5Y91.74%
EBIT growth 1Y-162.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5361.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4294.44%
OCF growth 3YN/A
OCF growth 5YN/A